METASTATIC CERVICAL CANCER Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate QL1706 Plus Paclitaxel-Cisplatin/Carboplatin With or Without Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy (Paclitaxel-cisplatin/Carboplatin) ± Bevacizumab; Control group: placebo + chemotherapy (paclitaxel-cisplatin/carboplatin) ± bevacizumab
Subjects must provide sufficient archival or newly obtained tumor tissue samples to determine PD-L1 expression level to be eligible for screening.During the screening phase, eligible subjects will be stratified by use of bevacizumab (yes vs no), prior concurrent chemoradiation therapy (yes vs no), and PD- L1 level (CPS < 1 vs 1 ≤ CPS < 10 vs CPS ≥ 10) and randomized 1:1 into the experimental or control arm.Experimental: QL1706 + Chemotherapy (Paclitaxel-cisplatin/Carboplatin) ± Bevacizumab;Control group: placebo + chemotherapy (paclitaxel-cisplatin/carboplatin) ± bevacizumab ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04266886 -
Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer
|
N/A | |
| Recruiting |
NCT04865887 -
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
|
Phase 2 | |
| Completed |
NCT00430781 -
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
|
Phase 2 | |
| Terminated |
NCT03786107 -
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
|
||
| Recruiting |
NCT06238635 -
Dostarlimab and Cobolimab in Advanced Cervical Cancer
|
Phase 2 | |
| Withdrawn |
NCT05614453 -
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
|
Phase 2 | |
| Terminated |
NCT03277482 -
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
|
Phase 1 | |
| Recruiting |
NCT00532818 -
Hydralazine Valproate for Cervical Cancer
|
Phase 3 | |
| Completed |
NCT04380805 -
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
|
Phase 2 | |
| Completed |
NCT03816553 -
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
|
Phase 2 | |
| Withdrawn |
NCT04943627 -
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
|
Phase 3 | |
| Recruiting |
NCT06313268 -
Safety of Effivia®, a Bevacizumab Biosimilar
|
||
| Terminated |
NCT04230954 -
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
|
Phase 2 |